Antibody Drug
Conjugate
Ask for advice
Expertise for complete and successful ADC development
ADC development requires a delicate balance to achieve sufficient potency: optimal targeted delivery, tolerability, stability, and developability. Efficient internalization of the ADC into tumor cells and the bystander effects of released payloads further influence efficacy and safety profiles.
The complexity of ADC design requires a world of expertise, from linker chemistry to payload selection, or antibody characteristics and manufacturing scalability. Moreover, numerous new formats are emerging, such as antibody fragment conjugates or degrader antibody conjugates (DACs), which further increase the options to be considered at each phase of drug development. This is where your partner, MImAbs, can secure and accelerate your program. With comprehensive expertise across the entire ADC design workflow.
Solving the ADC Puzzle
Design optimal targeted delivery
Achieve
sufficient potency
Ensure stability, developability and tolerability
Proven ADC
know-how
Access to specialized know-how in antibody engineering, conjugation strategies, and ADC design.
See the serviceExclusive Integrated
ADC Library program
An accelerated pipeline enabling early lead selection, extensive payload comparison, developability assessment, and streamlined progression toward downstream preclinical
proof-of-concept
Risk-adjusted
development
Leveraging MImAbs’ experience to anticipate
challenges in linker chemistry, payload selection, hydrophobicity, stability, and overall developability.
Robust preclinical candidates
ADCs supported by extensive analytical
profiling and functional validation, providing strong confidence to move forward
into preclinical studies.
Partnering with MImAbs
can accelerate your program
With comprehensive expertise across the entire ADC workflow, we guide you through every step.
mAb Generation
- Immunization
- Multiplex screening
- Sequencing
- Bioinformatics analysis
Bioproduction
- Expression vectors with
engineered Fc regions - Transient expression
- Purification / Formulation
Drug Conjugation
- Linker and drug selection
- Engineering of conjugation sites
- Generation of ADC libraries
- Purification and Quality
Functionnal Characterization
- Affinity measurements
- Biochemical characterization
- Developability assessment
- Cytotoxicity assays
Biological Efficacy
- Selection of models
- PK & PD profiling
- Efficacy, Safety and Toxicity
Accelerate your development with the ADC Library Program
Designed for the fast development of ADCs from
candidate antibodies, enabling early efficacy evaluation.
The program includes :
- Site-specific conjugation of a set of antibodies with a single linker–payload at controlled DAR, purification, and ADC characterization.
- In vitro functional assays (EC50, affinity, cytotoxicity) to select the best antibodies.
- Conjugation of the most promising antibody leads to a library of linker–payloads at optimal DAR according to drug toxicity, purification, DAR/homogeneity assessment, and functional assays.
- Preliminary stability and aggregation testing
Conjugation of diverse
antibodies with a generic
linker-payload
In vitro functional
assays
Payload library –
Screening diverse
linker-payload combinations
In vitro functional
assays, stability and aggregation testing
Examples of ADCs application
Talk to one of our expert
Need expert support in ADC ?
Contact MimAbs to discuss your project, our team will support you in the scientific study and strategic development planning of your project.
Contact an expert